CME (AMA PRA Category 1 Credit)

  2. Home
  3. Credit Type
  4. CME (AMA PRA Category 1 Credit)
  5. Specialty Area
  6. Hematology
Page 1 of 2
Results 1 - 75 of 80
9278-isth-explore
Hemophilia Gene Therapy: Shared Decision Making - Clinical Companion Guide
9275-pnh-mod1
Understanding PNH and Other Complement-mediated Hematologic Disorders
9275-pnh-mod2
Getting to Know PNH
9275-pnh-mod3
Current and Emerging Treatment Options in PNH
9277-mod1
Understanding Myelofibrosis
9277-mod2
Risk Stratification in Myelofibrosis Management
9277-mod3
Current and Emerging JAK Inhibitors
9278-isth-explore
Risks and Benefits of Hemophilia Gene Therapy: An EXPLORE Learning Experience
9268-aTTP
A Hematologic Emergency: Would You Miss iTTP? - Rapid Recap
cttp_thumb_264x150
cTTP: Protecting Patients, Today and Tomorrow - Rapid Recap
9280 rett
Rett Syndrome: Delayed Diagnosis, Patient Perspectives & Evolving Treatment - Rapid Recap
9280 rett
Rett Syndrome: Delayed Diagnosis, Patient Perspectives & Evolving Treatment - Slide Deck
9280 rett
Rett Syndrome: Delayed Diagnosis, Patient Perspectives & Evolving Treatment
9268-aTTP
A Hematologic Emergency: Would You Miss iTTP?
9232-module1
Identify the Etiology of Aplastic Anemia in Patients
9232-module2
Recognizing Risk and Benefits of Management Options for Aplastic Anemia
9232-module3
Considerations for Special Populations With Aplastic Anemia
9171-ash-explore
Gene Therapy for Hemophilia: An EXPLORE Learning Experience
cttp_thumb_264x150
cTTP: Protecting Patients, Today and Tomorrow
9155-cart-cell
CAR T-Cell Therapy Consults: Navigating a New Landscape
9167-0001-263x149
Treating Persistent/Chronic ITP: Current Care, Future Potential
No image set
Strategies for Assessing and Managing DOAC-Related Bleeding
No image set
Managing Side Effects of Newer Therapies for Acute Lymphoblastic Leukemia (ALL)
No image set
Emerging Treatments in Chronic GvHD
No image set
Treatment of Ph+ Relapsed/Refractory ALL
No image set
Treatment of Ph- Relapsed/Refractory ALL
9143 Thumb
Emerging Nonfactor Approaches for Patients with Hemophilia
No image set
Identification of Relapsed ALL
No image set
Principles of Management of Chronic GVHD
No image set
Diagnosing and Assessing Chronic Graft-versus-Host Disease
No image set
Reversing DOACS: Providing Answers to What, Where and How
No image set
Reversing DOACS: Recording from Live Session held on July 18, 2021
No image set
Conquer the Clot: Addressing VTE in Your Patients with Cancer
9076-0001-263x149
Healthcare Disparities in African Americans With Myeloma
No image set
Key Considerations: Advances in Gene Therapy for Hemophilia
No image set
Highlights From the EAHAD 2021 Virtual Congress
No image set
Updated Follow-up of the Alta Study, Giroctocogene Fitelparvovec (SB-525)
No image set
First Data From the Phase 3 HOPE-B Gene Therapy Trial
No image set
The World Federation of Hemophilia Gene Therapy Registry
No image set
Etranacogene Dezaparvovec, an Enhanced Vector for Gene Transfer in Adults (Pipe)
No image set
AMT-060 Gene Therapy in Adults With Severe or Moderate-Severe Hemophilia B (Leebeek)
No image set
AMT-060 Gene Therapy in Adults With Severe or Moderate-Severe Hemophilia B (Miesbach)
No image set
First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology
No image set
Characterisation of Adeno-Associated Virus Vector Persistence
No image set
Follow-up on a Novel Adeno-Associated Virus (AAV) Gene Therapy (FLT180a)
No image set
Etranacogene Dezaparvovec, an Enhanced Vector for Gene Transfer in Adults (Drygalski)
No image set
Efficacy and Safety of Etranacogene Dezaparvovec in Adults
No image set
Thrombotic Thrombocytopenic Purpura (TTP) Podcasts
No image set
Cancer-Associated Thrombosis: Catheter-related Thrombosis (CRT) VTE
No image set
Approach to the Patient With Cancer-associated VTE
No image set
Cancer-Associated Thrombosis: Primary Prophylaxis
No image set
Understanding and Recognizing TTP
No image set
How to Treat iTTP in 2020
No image set
TTP: Complexities and Comorbidities
No image set
Monitoring of Immnune Mediated TTP
No image set
Diagnosis of TTP
No image set
Key Considerations: Advances in Gene Therapy for Hemophilia
No image set
Integrating Emerging Treatments for Hemophilia A
No image set
Genomics Essentials In Hematologic Malignancies (GENOM)
No image set
Gene Therapy for Treatment of Hemophilia: An Introduction to AAV Vector Gene Transfer
No image set
Gene Therapy for Treatment of Hemophilia: Other Strategies and Targets
9915-conf_covg_icon_263x149
Conference Coverage from ISTH 2019 in Melbourne
9915-mod3-icon
A History of Hemophilia Treatment: Non-replacement Therapy to Gene Therapy
No image set
Gene Therapy for Treatment of Hemophilia: Common Concerns in Gene Therapy
9915-mod2-icon
A History of Hemophilia Treatment: Factor Replacement to Gene Therapy
9915-mod1-icon
Getting to Know Gene Therapy: Terminology and Concepts
hopa-icon8
Biosimilars: Applying the Science to Hematology/Oncology Practice
biosims-archmed icon
Top Questions about Biosimilars in Hematology/Oncology
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
IL-fund-case1
What is a Biologic?
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
Page 1 of 2

Search